autologous peripheral blood mononuclear cells + filgrastim

This is a **combination cell therapy** consisting of autologous peripheral blood mononuclear cells (PBMNCs) and filgrastim (granulocyte colony-stimulating factor, G-CSF). PBMNCs are a heterogeneous mix of blood cells with a round nucleus, including lymphocytes (T cells, B cells, NK cells), monocytes, and progenitor cells, sourced from the patient's own peripheral blood[5][1]. Filgrastim is administered to mobilize these cells from the bone marrow into peripheral blood prior to collection[1]. The therapy is typically used for **critical limb ischemia (CLI), no-option CLI, and diabetic foot ulcers**, aiming to induce therapeutic angiogenesis—formation of collateral blood vessels—through paracrine signaling of growth factors, cytokines, and messenger molecules produced by PBMNCs[3][7]. Filgrastim acts as a mobilizer, increasing the yield of PBMNCs and potentially enhancing their regenerative and angiogenic properties. The main mechanism involves tissue regeneration, angiogenesis, immune modulation, and M1-to-M2 macrophage polarization (inflammatory to regenerative phenotype)[3][7]. Cell therapy with autologous PBMNCs + filgrastim is considered minimally invasive compared to bone marrow-based approaches, and can be repeated as required[3]. The combination is under clinical investigation and is not widely approved outside clinical trials.

Other names

autologous PBMNCs + filgrastimautologous peripheral blood mononuclear cell therapy + G-CSF